Handelsavisen
prelaunch
Companies Healthcare 261780.KQ
26
261780.KQ KOSDAQ Biotechnology & Medical Research

261780.Kq

$2 970,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
79,8B KRW
P/E
EV / Rev
Div yield
Op margin
-9 124,0 %
ROE
-135,3 %
Net margin
-10 115,3 %
Debt / equity
0,75
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.

Business. The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-135,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 261780.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 261780.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a high debt-to-equity ratio of 0.75, indicating a moderate reliance on debt financing. The liquidity position is assessed as medium, with a current ratio of 1.66, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's negative operating and free cash flows, at -11,017.07 million KRW and -15,744.78 million KRW respectively, indicate a lack of cash generation from operations.

    Profitability metrics are weak, with a return on equity (ROE) of -1.35 and a return on assets (ROA) of -0.54, both significantly below the industry median. The company's net loss of -16,044.49 million KRW and operating loss of -14,472.08 million KRW further underscore its unprofitable operations. Gross profit of 14,391.82 million KRW is the only positive earnings metric, but it is insufficient to offset the company's operational costs.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow and free cash flow are both negative, indicating a lack of internal cash generation to fund future growth. The company's capital expenditures of -155.92 million KRW suggest a minimal investment in long-term assets, which may limit its ability to scale operations or develop new products.

    The company's risk profile is elevated, with a medium liquidity risk and a low dilution risk. The company's negative net cash position, after subtracting total debt, is a key flag indicating potential liquidity constraints. The company's dilution risk is low, with no significant dilution potential reported in the available data. However, the company's high debt levels and negative cash flows may necessitate future financing, which could lead to dilution if equity is used to raise capital.

    Recent events, as disclosed in the company's financial filings, include a significant operating and net loss, which may impact investor confidence. The company has not disclosed any recent strategic initiatives or product launches that could drive future revenue growth. The absence of recent positive developments may contribute to a bearish outlook for the company's stock.

    Key takeaways
    • The company is operating at a significant net and operating loss, with negative cash flows from operations.
    • The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.75.
    • The company's profitability metrics are weak, with a negative return on equity and return on assets.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company's liquidity position is medium, with a current ratio of 1.66, but it has negative operating and free cash flows.
    • The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2 970,00
    Market cap
    $86.64B
    Enterprise value
    $95.48B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    7.3x
    P / Tangible book
    7.3x
    Tangible book
    $11.86B
    Net cash
    -$8.84B
    Current ratio
    1.7
    Debt / equity
    0.8
    ROA
    -53.9%
    ROE
    -1.4%
    Cash conversion
    69.0%
    CapEx / revenue
    -98.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-9 124,0 %Bottom quartile
    Net Margin-10 115,3 %Bottom quartile
    ROE-135,3 %Bottom quartile
    Capex / Rev-98,3 %Bottom quartile
    D/E0,75Bottom quartile
    Cash Conv0,69Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 261780.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    261780.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage